2m 2m 2m 2m 2m 2m 2m
COMPASS THERAPTC (CMPX)
NASDAQ
$2.07+$0.006 (+0.29%)
Price as of Jun 23, 2026 7:53 PM EDT- $378.2MMarket Cap
- -17.32%1-Year Change
- BiotechnologyIndustry
COMPASS THERAPTC (CMPX)
$2.07+$0.006 (+0.29%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 0 -100.00% | 850,000 N/A | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 -100.00% | 850,000 N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -56.0M +32.18% | -42.3M +11.08% | -38.1M +27.08% | -30.0M -57.72% | |
Depreciation and Amortization Expense | 276,000 -53.14% | 589,000 -15.74% | 699,000 -10.61% | 782,000 +38.16% | |
Total Operating Expenses | 72.8M +26.73% | 57.5M +14.12% | 50.4M +20.91% | 41.7M -49.13% | |
Operating Profit | -72.8M +28.63% | -56.6M +12.43% | -50.4M +20.91% | -41.7M -49.13% | |
Interest Income | 6.4M -12.33% | 7.3M -7.23% | 7.9M +233.43% | 2.4M +8,037.93% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | 0 +100.00% | |
Interest Income and Expense and Net | 6.4M -12.33% | 7.3M -7.23% | 7.9M +233.43% | 2.4M +792.08% | |
Total Nonoperating Income and Expense | 6.3M -12.41% | 7.3M -7.87% | 7.9M +223.83% | 2.4M +912.71% | |
Income before Taxes | -72.8M +28.63% | -56.6M +33.25% | -42.5M +8.33% | -39.2M -52.27% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -66.5M +34.66% | -49.4M +16.19% | -42.5M +8.33% | -39.2M -52.27% | |
Net Income from Continuing Operations Applicable to Common | -66.5M +34.66% | -49.4M +16.19% | -42.5M +8.33% | -39.2M -52.27% | |
Basic EPS and Net Income | -0.42 +16.67% | -0.36 +9.09% | -0.33 -10.81% | -0.37 -71.76% | |
Diluted EPS and Net Income | -0.42 +16.67% | -0.36 +9.09% | -0.33 -10.81% | -0.37 -71.76% | |
Basic Weighted Average Shares | 157.7M +14.78% | 137.4M +8.15% | 127.0M +20.76% | 105.2M +67.31% | |
Diluted Weighted Average Shares | 157.7M +14.78% | 137.4M +8.15% | 127.0M +20.76% | 105.2M +67.31% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 30.6M -29.53% | 43.5M +79.47% | 24.2M -30.67% | 34.9M -75.82% | |
Short-Term Investments | 178.3M +114.16% | 83.2M -35.09% | 128.2M -15.45% | 151.7M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 208.9M +64.85% | 126.7M -16.88% | 152.5M -18.30% | 186.6M +29.13% | |
Total Current Assets | 209.8M +58.05% | 132.8M -13.73% | 153.9M -21.00% | 194.8M +32.42% | |
Accumulated Depreciation | 6.6M +4.34% | 6.4M +1.50% | 6.3M +12.55% | 5.6M +10.78% | |
Property and Plant and Equipment and Net | 102,000 -71.10% | 353,000 -60.69% | 898,000 -42.69% | 1.6M -30.14% | |
Total Long-Term Assets | 102,000 -82.04% | 568,000 +77.50% | 320,000 0.00% | 320,000 0.00% | |
Total Assets | 219.6M +56.40% | 140.4M -10.50% | 156.9M -21.42% | 199.6M +29.84% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 14.0M +57.40% | 8.9M +13.75% | 7.8M -51.75% | 16.2M +52.09% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 8.8M +40.23% | 6.3M +1,074.63% | 536,000 -70.84% | 1.8M -39.70% | |
Total Liabilities | 22.8M +50.28% | 15.2M +81.96% | 8.3M -53.70% | 18.0M +31.64% | |
Retained Earnings | -431.2M +18.23% | -364.7M +15.66% | -315.3M +15.58% | -272.8M +16.79% | |
Total Stockholders Equity | 196.8M +57.14% | 125.2M -15.69% | 148.5M -18.22% | 181.6M +29.67% | |
Total Shares Outstanding | 178.3M +29.39% | 137.8M +7.95% | 127.7M +1.08% | 126.3M +25.26% | |
Cash Flow | |||||
Cash from Operating Activities | -49.1M +9.56% | -44.9M +10.43% | -40.6M +19.03% | -34.1M +73.52% | |
Capital Expenditures | 25,000 -43.18% | 44,000 +46.67% | 30,000 -85.85% | 212,000 -86.48% | |
Cash from Investing Activities | -93.3M -299.49% | 46.8M +73.45% | 27.0M +117.83% | -151.2M +8,442.37% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 129.6M +647.54% | 17.3M +490.73% | 2.9M -96.13% | 75.8M -36.13% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | -6,661.76% N/A | N/A N/A | N/A N/A | |
Return on Assets | -36.94% +11.20% | -33.22% +39.35% | -23.84% +7.39% | -22.20% -72.22% | |
Return on Equity | -41.29% +14.48% | -36.07% +40.13% | -25.74% +5.56% | -24.38% -73.29% | |
Revenue Growth | -100.00% N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 15.02 +0.41% | 14.96 -24.16% | 19.73 +63.74% | 12.05 -12.94% | |
Cash Ratio | 2.19 -55.23% | 4.90 +57.77% | 3.11 +43.70% | 2.16 -84.10% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow